Skip to main content
. Author manuscript; available in PMC: 2014 Oct 24.
Published in final edited form as: Oncogene. 2013 May 27;33(17):2215–2224. doi: 10.1038/onc.2013.172

Figure 3. Progestin induces BCL6 expression and prolactin suppresses progestin-induced BCL6.

Figure 3

(A) Immunoblots of BCL6, CK5, and GAPDH protein levels of T47D cells treated with the synthetic progestin R5020 (Pg) at the indicated doses for 24 h (top), or the indicated times with 20nM R5020 (Pg) (bottom). (B) Immunoblots of BCL6 protein in extracts of T47D cells treated with vehicle (Cntrl), Prolactin (PRL), β-Estradiol (E2), or R5020 (Pg) for the indicated times. (C) Immunoblots of BCL6, CK5, and GAPDH protein levels in extracts of T47D cells treated with hormones in the presence or absence of the progesterone receptor antagonist RU486 for 48 h. (D) Immunoblots of BCL6, phosphorylated-Stat5 (p-Stat5), and GAPDH protein levels in extracts of T47D, MCF-7, ZR75-1, BT-474, and HCC1937 cells treated with hormones for 72 h.